Inorganica Chimica Acta 402 (2013) 109-115

Contents lists available at SciVerse ScienceDirect

Inorganica Chimica Acta

journal homepage: www.elsevier.com/locate/ica

Vanadocene and niobocene dihalides containing electron-withdrawing substituents in the cyclopentadienyl rings: Synthesis, characterization and cytotoxicity

Iva Klepalová^a, Jan Honzíček^b, Jaromír Vinklárek^{a,*}, Zdeňka Padělková^a, Lucie Šebestová^c, Martina Řezáčová^d

^a Department of General and Inorganic Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic ^b Institute of Chemistry and Technology of Macromolecular Materials, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic ^c Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic ^d Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, 500 01 Hradec Králové, Czech Republic

ARTICLE INFO

Article history: Received 26 November 2012 Received in revised form 7 January 2013 Accepted 3 March 2013 Available online 24 March 2013

Keywords: Metallocene dihalides EPR spectroscopy X-ray crystallography Leukemia therapy Cytotoxicity

1. Introduction

ABSTRACT

The first example of the group V metallocene dihalides substituted in the cyclopentadienyl rings with electron-withdrawing substituents is reported. This study includes synthesis and spectroscopic characterization of the series of vanadocene and niobocene compounds functionalized in the cyclopentadienyl rings with the ester groups. Structures of (η^5 -C₅H₄COOPh)₂VCl₂, (η^5 -C₅H₄COOMe)₂VBr₂·CH₂Cl₂, (η^5 -C₅H₄COOPh)₂NbCl₂, (η^5 -C₅H₄COOMe)₂NbBr₂ and (η^5 -C₅H₄COOEt)₂NbBr₂ were determined by X-ray diffraction analysis. Cytotoxic activity toward human leukemia cells MOLT-4 was established *in vitro* for all newly prepared metallocene compounds.

© 2013 Elsevier B.V. All rights reserved.

gether with other weak points of titanocene dichloride (*e.g.*, complex hydrolytic behavior) led to design of the modified titanocene, vanadocene and molybdenocene compounds. The preclinical studies on *cis*-platin resistant tumor cell lines are proving that the cytotoxicity of the titanocene complexes could be enhanced through the substitution in the cyclopentadienyl ring. Promising results were obtained mainly for aminoalkyl [18–20], methoxycarbonyl [21] and methoxybenzyl functionalized compounds [22]. So far, only few studies have been focused in metallocene containing other metal than titanium. The high cytotoxicity was found only in case of the vanadocene [23–27] and molybdenocene compounds [28] containing methoxy-benzyl substituted cyclopentadienyl rings.

Our focus on the modification and the application of the group V metallocene compounds follows our previous studies attended in leukemia therapy [23,29,30] and corresponds with our long-standing interest in the chemistry of metallocene compounds [31,32]. The introduction of the ester group in the cyclopentadienyl rings was chosen due to promising biological properties of the titanocene analogues with similar structure pattern [21]. Furthermore, this study brings the first example of the group V metallocene dihalides modified with strong electron withdrawing groups in the cyclopentadienyl ligands and describes their effect on the structure and EPR spectra.

0020-1693/\$ - see front matter © 2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.ica.2013.03.018

* Corresponding author. Fax: +420 46603 7068.

E-mail address: jaromir.vinklarek@upce.cz (J. Vinklárek).

Design of the metal-based anticancer drug superior or at least

complement to cisplatin become the challenge of the inorganic

chemists in last few decades [1-5]. The bent metallocenes Cp_2MCl_2

 $(Cp = \eta^5 - C_5 H_5; M = \text{group IV} - VI \text{ metal})$ were the first class of the

organometallic compounds to be systematically investigated for

this purpose [6] and remain under comprehensive scrutiny up to

now. The early stage of the investigation have shown that the

bis-cyclopentadienyl complexes of Ti(IV) [7], V(IV) [8], Nb(IV) [9],

Nb(V) [10], Mo(IV) [11] and Mo(VI) [10] are active toward Ehrlich

ascites tumor cells while complexes of the other metals from group

IV, V and VI are much less active or inactive [12]. This rule seems to

be more general. It may be applied also for other cancer cell lines

and for substituted derivatives with only few exceptions [13,14].

dichloride that has passed though the preclinical and phase I clin-

ical trials [15]. However, the phase II trials have concluded that this

agent is not effective in patients with metastatic breast cancer [16]

and metastatic renal-cell carcinoma [17]. These objections to-

The first stage of the scrutiny was focused mainly on titanocene











Scheme 1. Synthesis of vanadocene complexes. (a) VCl₃(THF)₃/THF; (b) PCl₃/Et₂O; (c) BBr₃/CH₂Cl₂.

2. Results and discussion

2.1. Synthesis of vanadocene and niobocene complexes

Ester-substituted vanadocene dichlorides $(\eta^5-C_5H_4COOR)_2VCl_2$ (**5**: R = Me, **6**: R = Et, **7**: R = Ph, **8**: R = CH₂CH₂OMe) were prepared by the reaction of VCl₃(THF)₃ with appropriate substituted sodium cyclopentadienide (1-4), see Scheme 1. The putative monochloride intermediates $(\eta^5-C_5H_4COOR)_2VCl$ were not isolated but their appearance was described previously for several *ansa*-vanadocene analogues [33]. The synthesis of the ring-substituted and ansabridged vanadocene dichlorides has been optimized previously [23,33–35]. It was shown that reactions of Grignard reagents Cp'MgCl (Cp' = substituted Cp) with $V(acac)_3$ or $V(acac)_2Cl(THF)$ are giving the vanadocene complexes in much higher yield than reaction of lithium or sodium cyclopentadienides with VCl₃(THF)₃. Unfortunately, this modification of the procedure could not be applied for ester-substituted vanadocenes because the starting (C₅H₄₋ COOR)MgCl is not accessible due to pronounced reactivity of the Grignard reagents with carboxylic acid esters.

The complexes **5** and **6** were further used for preparation of the dibromide complexes $(\eta^5-C_5H_4COOMe)_2VBr_2$ (**9**: R = Me, **10**: R = Et). The ligand-exchange reaction was done in dichloromethane using the boron tribromide (Scheme 1). This protocol was chosen for ester-functionalized vanadocene complexes mainly due to mild reaction conditions and fast reaction rate [35].

Niobocene dichloride complexes $(\eta^5-C_5H_4COOR)_2NbCl_2$ (11: R = Me, 12: R = Et, 13: R = Ph, 14: R = CH_2CH_2OMe) were prepared by the reaction of NbCl₄(THF)₂ with appropriate substituted sodium cyclopentadienide (1–4), see Scheme 2. This method is a modification of the protocol developed for the unsubstituted niobocene dichloride [36]. The dibromide complexes 15 and 16 were prepared similarly as the vanadocene analogues by reaction of niobocene dichlorides (11 and 12) with boron tribromide. Synthesis of the starting compounds **1–3** was done according to literature procedures [37–39]. The cyclopentadienide **4** was prepared according to Scheme 3. Base-catalyzed transesterification [40,41] of dimethyl carbonate with 2-methoxy-ethanol gives bis(2-methoxyethyl) carbonate (**17**). Following reaction with so-dium cyclopentadienide gives compound **4** in medium yield. The infrared spectrum of the compound **4** shows strong band of the CO stretching at 1641 cm⁻¹ that proves the attachment of ester group. The assembly of substituted cyclopentadienide was further evidenced by spectroscopic characterization of the molybde-num(II) complex [(η^3 -C₃H₅)(η^5 -C₅H₄COOCH₂CH₂OMe)Mo(CO)₂] (**18**) that was prepared by reaction of the compound **4** with [(η^3 -C₃H₅)Mo(CO)₂(NCMe)₂CI], see Scheme 4.

2.2. Spectroscopic characterization of vanadocene and niobocene complexes

The infrared spectra of the vanadocene complexes **5–10** and niobocene complexes **11–16** show characteristic band of C=O stretching at 1720–1751 cm⁻¹; see Table 1. These high wavenumbers indicate low delocalization of the π -electrons from C=O group that is compatible with expected η^5 -coordination mode. The starting



Scheme 4. Synthesis of compounds 18. (a) $[(\eta^3-C_3H_5)Mo(CO)_2(NCMe)_2CI]/THF$.



Scheme 2. Synthesis of niobocene complexes 15 and 16. (a) NbCl₄(THF)₂/THF; (b) BBr₃/CH₂Cl₂.



Scheme 3. Synthesis of cyclopentadienide 4. (a) (MeO)₂CO, NaOMe ; (b) NaCp/THF.

Download English Version:

https://daneshyari.com/en/article/7751750

Download Persian Version:

https://daneshyari.com/article/7751750

Daneshyari.com